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INTRODUCTION
Refinements in pediatric acute lymphoblastic leukemia (ALL)
treatment from collaborative clinical trials have achieved cure rates
of 85% [1] and 5-year event-free survival (EFS) of 80% [2].
Relapsed leukemia remains the commonest cause of pediatric
cancer death.
Allogeneic hematopoeitic stem cell transplantation (HSCT) in
pediatric ALL is considered using clinical and laboratory features
such as length of first remission in relapsed patients and minimal
residual disease (MRD) in first remission [3]. MRD monitoring has
facilitated risk stratification and treatment selection [3–8].
Allogeneic HSCT indications are evolving [9,10], as survival
with chemotherapy-only treatment improves [3,4,9,11].
Donor sources for HSCT have changed over the last 25 years. A
matched sibling donor (MSD) was historically preferred over
unrelated donors, due to perceived transplant-related mortality
(TRM) risk [12–14]. LimitedMSD availability has prompted use of
alternate donors, including family-related donors (FRD), matched
unrelated donors (MUD), and matched unrelated cord blood
transplants (UCT). UCT is increasingly used, due to factors
including wider range of compatible donors and ease of
availability [15]. In childhood ALL, alternate donor HSCTs
comprise 61% of allografts (1999–2002) [14] whereas prior to
1996, MSD accounted for 70% of HSCT [14]. UCT now accounts
for one-third of HSCT for acute leukemia [16].
With the advent of alternate donor HSCT, TRM risk has
increased [17]. Audits of adult patients demonstrate this [17,18]. In
addition, relapsed patients often require greater myelosuppression
to achieve pre-HSCT remission [16,18–20], with consequences of
increased pre-HSCT comorbidities and infective burden. Despite a
higher recent predicted TRM, one study involving adults showed
significant improvement in survival and reduction in overall
mortality, including non-relapse and relapse mortality [18]. TRM
figures for pediatric HSCT, including ALL patients, are 5–10% for
MSD [3,21,22], 8–24% for MUD [3,16,21,22], and over 20% for
mismatched donors [3,21,23]. Earlier TRM figures for unrelated
donor HSCT in pediatric ALL were 16–42% [22,24,25].
Although there are general trends of improved overall survival
(OS) and reduced TRM [17,26,27] following HSCT, few studies
have discussed temporal trends in pediatric ALL HSCT [16,22,25].
We analyzed our experience with pediatric HSCT between 1984
and 2009 in ALL.We hypothesized that OS in our allogeneic HSCT
cohort had improved, despite increase in unrelated donor HSCT.
PATIENTS AND METHODS
Data Collection
A retrospective review of 136 consecutive allogeneic HSCT for
ALL at Sydney Children’s Hospital was conducted. Data from 1/1/
1984 to 31/12/2009 were analyzed from the Cord & Marrow
Transplant database at Sydney Children’s Hospital. Comprehensive
Background: Over the last 25 years, donor source, conditioning,
graft-versus-host disease prevention and supportive care for children
undergoing hematopoeitic stem cell transplantation (HSCT) have
changed dramatically. HSCT indications for acute lymphoblastic
leukemia (ALL) now include high-risk patients in first and subsequent
remission. There is a large burden of infectious and pre-HSCT
morbidities, due to myelosuppressive therapy required for remission
induction. We hypothesized that, despite these trends, overall
survival (OS) had increased. Procedure: A retrospective audit of
allogeneic pediatric HSCT for ALL was performed in our institution
over 25 years. Outcomes for 136 HSCTs were analyzed in three
consecutive 8-year periods (Period 1: 1/1/1984–31/8/1992, Period 2:
1/9/1992–30/4/2001, Period 3: 1/5/2001–31/12/2009). Results:
Despite a significant increase in unrelated donor HSCT, event-free
and OS over 25 years improved significantly. (EFS 31.6–64.8%,
P¼0.0027; OS 41.8–78.9%, P<0.0001) Concurrently, TRM
dropped from 33% to 5% (P¼0.0004) whilst relapse rate was static
(P¼0.07). TRM reduced significantly for matched sibling and
unrelated cord blood transplantation (UCT) in Period 3 compared
with earlier periods (P¼0.036, P¼0.0098, respectively). Factors
leading to improved survival in patients undergoing UCT include
better matching, higher total nucleated cell doses, and significantly
faster neutrophil engraftment. Length of initial HSCT admission was
similar over time. Conclusion: EFS and OS have increased
significantly despite heightened HSCT complexity. This survival
gain was due to TRM reduction. Contemporary patients have
benefited from refined donor selection and improved supportive
care. Overall rates of leukemic relapse post-HSCT are unchanged,
and remain the focus for improvement. Pediatr Blood Cancer 2013;
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data were collected prospectively in the Transplant database with
internal and external audits to assess data accuracy. The data set was
censored at 31/12/2010. Data for survivors were censored at date of
last follow-up. This study received institutional ethics committee
approval.
The study periodwas divided into three time frames (Period 1: 1/
1/1984–31/8/1992, Period 2: 1/9/1992–30/4/2001, Period 3: 1/5/
2001–31/12/2009) and HSCT outcomes analyzed. Time frames
reflected changes in choice of alternate donors, with predominant
use of FRD in Period 1, MUD in Period 2 and UCT in Period 3.
Similar numbers of HSCTwere performed in each period (Table I).
Patients who received HSCT in CR1 fulfilled high-risk or very
high-risk features on ALL protocols used. Risk stratification was
based on Berlin–Frankfurt–Munster (BFM) criteria, and incorpo-
rated MRD criteria in Period 3.
Conditioning regimens varied according to transplant period
(Table I). There was a significant increase in TBI use (P< 0.01),
with predominantly TBI-based conditioning in Period 3. Four
reduced-intensity transplants were performed in Period 3, one
upfront and three for post-HSCT relapse. In Period 3, 12.5% of
patients who received TBI-based myeloablative conditioning also
received a CNS boost. No CNS boost was administered in earlier
periods. TBI was generally avoided in those aged under 2 years at
time of HSCT. Overall, 89% of chemotherapy-alone conditioning
contained cyclophosphamide and busulphan. In Period 1, a regimen
of busulphan, cyclosphosphamide, and melphalan was used in 74%
of HSCT episodes. The combination of busulphan, cyclosphamide,
and etoposide was used in 53% of HSCT in Period 2. Busulphan
levels were not obtained. Anti-thymocyte globulin (Pfizer) was used
for UCT and MUD HSCT at 12mg/kg/dose for three doses,
including T-cell-depleted MUD HSCT. Anti-thymocyte globulin
was prophylaxis for rejection and graft-versus-host disease
(GVHD).
Graft characteristics are shown in Table I. The majority of
patients who underwent MUDHSCT received bone marrow. Tissue
typing and HLA matching were performed by the Australian Bone
Marrow Donor Registry (ABMDR) using established international
methods [28,29]. High-resolution typing for DRB1 has been used
since the late 1990s and high-resolution typing for Class 1 allele
(HLA-ABC) testing has been routine in recent years [22]. UCT
were 4/6 matches or better (Table III). FRD were mostly one to two
antigen mismatches, and included mismatched siblings, parents or
relatives. In Period 1, one FRD was a haploidentical parent.
Supportive care practices in our unit varied prior to 2004. We
used graft support with colony-stimulating factor from 1991 for
unrelated donor HSCT. Cyclosporine was the consistent backbone
of GVHD prophylaxis. For patients receiving MSD HSCT after
2004, cyclosporine and methotrexate were given as GVHD
prophylaxis. Patients transplanted using single UCT prior to
2004 received cyclosporine, methylprednisone, and methotrexate
TABLE I. Characteristics of Each Period
Period 1
1/1/1984–31/8/1992
Period 2
1/9/1992–30/4/2001
Period 3
1/5/2001–31/12/2009 P-value
Number of HSCTa 41 48 47
Number of patients 40 46 44
Baseline characteristics
Males 30 (73.2%) 35 (72.9%) 31 (66%) 0.7
Median age (months) at HSCT (range) 117 (9–235) 97 (10–206) 108 (17–221) 0.48
Median time (months) from diagnosis to HSCT (range) 36 (4–114) 34 (5–122) 23 (4–80) <0.01
Remission status
CR1 4 (9.8%) 4 (8.3%) 15 (31.9%) 0.003
CR2 23 (56.1%) 35 (72.9%) 25 (53.2%) 0.108
CR3 12 (29.3%) 7 (14.6%) 5 (10.6%) 0.058
CR4 1 (2.4%) 1 (2.1%) 0 0.59
Not documented 0 0 2 (4.3%) N/Ah
Persistent disease 1 (2.4%) 1 (2.1%) 0 N/Ah
Radiotherapy administered prior to HSCT conditioning 12 (29.3%) 11 (22.9%) 1 (2.13%) <0.01
Graft type
MSDb 27 (65.9%) 20 (41.7%) 15 (31.9%) 0.02
UCTc 0 8 (16.7%) 21 (44.7%) <0.01
MUDd 2 (4.9%) 12 (25%) 10 (21.3%) 0.033
FRDe (Haplo/MMSDf) 12 (29.3%) 8 (16.7%) 1 (2.1%) 0.002
T cell depletion 8 (19.51%) 16 (33.3%) 10 (21.3%) 0.25
Conditioning type
TBI-based conditioning 15 (36.6%) 31 (64.6%) 45 (95.7%) <0.01
Chemotherapy alone 26 (63.4%) 17 (35.4%) 2 (2.1%) <0.01
CMV status (donor/recipient)
D/Rg 16 (39%) 14 (29.2%) 25 (53.2%) 0.06
D/Rþ 3 (7.3%) 8 (16.7%) 11 (23.4%) 0.125
Dþ/Rþ 10 (24.4%) 16 (33.3%) 5 (10.6%) 0.03
Dþ/R 9 (22%) 9 (18.8%) 6 (12.8%) 0.52
Not tested 3 (7.3%) 1 (2.1%) 0 N/Ah
aHematopoeitic stem cell transplant; bMatched sibling donor; cUmbilical cord blood transplant; dMatched unrelated donor; eFamily-related donor;
fMismatched sibling donor; gD/R denotes that pre-transplant CMV status is negative for donor, negative for recipient; hP-value not generated as
numbers for analysis are too small.
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for GVHD prophylaxis, whereas only cyclosporine and methyl-
prednisone were used after 2004. Cyclosporine and mycophenolate
were used for GVHD prophylaxis in patients receiving double UCT.
For patients undergoing MUD HSCT prior to 2000, cyclosporine
and red cell E-rosette were used for GVHD prophylaxis, whilst
cyclosporine and CD34 selection together were used after 2000.
Penicillin prophylaxis was used in Period 3 for patients with GVHD.
In Period 3, patients who were CMV IgG positive received
ganciclovir therapy (pre-HSCT and post-engraftment) and weekly
CMV immunoglobulin to Day þ100. Qualitative CMV PCR
monitoring was routine from 2004 and quantitative PCR from 2008.
PJP (Pneumocystis jirovecii pneumonia) prophylaxis included
routine pentamidine (since 2004) and cotrimoxazole post-engraft-
ment. Patients who were HSV IgG positive received aciclovir.
Additional changes from 2004 were routine antifungal prophylaxis
—fluconazole for standard risk and liposomal amphotericin or
voriconazole for patients at high risk of fungal disease; routine
ursodeoxycholic acid for veno-occlusive disease prophylaxis [30],
with additional prophylactic defibrotide for high-risk patients [31].
Features indicating higher VOD risk included heavily pre-treated
patients, prior HSCT, underlying liver dysfunction, hepatic iron
overload, and causative drugs [32].
Statistical Analysis and Definitions
OS, EFS, leukemia-free survival (LFS), TRM, and cumulative
incidence of relapse were analyzed from time of HSCT. Kaplan–
Meier survival curves were constructed [18,33] and sub-analyses
performed to compare survival according to graft type, period of
HSCT, and remission status. Survival outcomes for Periods 1 and 2
were not statistically different and were combined for analysis.
Each HSCTepisodewas analyzed separately for survival and TRM.
An event was defined as relapse, TRM, death from any cause or
second malignancy. TRMwas defined as death due to complication
(other than relapse) following HSCT. LFS was defined as alive,
without evidence of leukemia, or leukemia-free death. A second
malignancy was defined as malignancy other than the primary
leukemia, occurring post-HSCT.
Viral, bacterial and fungal infections were analyzed as recorded
on the Transplant database. Neutrophil engraftment was defined as
the first of three consecutive days of ANC 0.5 109/L. Platelet
engraftment was defined as unsupported platelet count>20 109/L.
Acute GVHD (aGVHD) was graded according to the Glucksberg
severity scale [34]. Chronic GVHD was GVHD occurring after Day
þ100 [34].
Statistical analysis was performed using PRISM (Prism 5,
GraphPad Software, Inc. 2005–2010). Two-sided P values
(Mantel–Cox Log Rank) were significant if below 0.05 and 95%
confidence intervals used. PASW Version 18 software was used for
variance analysis (ANOVA, t tests, Kruskall Wallis chi-squared
tests, Cox-regression).
RESULTS
Patient Population
An overview of HSCT characteristics and outcomes is shown in
Tables I and II, respectively. The groups had similar pre-HSCT
characteristics, apart from remission status and time from diagnosis
to HSCT. Therewas a significant increase in patients transplanted in
CR1 in Period 3 (P¼ 0.003). This increase reflected use of HSCT
for patients with high-risk disease based on MRD. The time from
diagnosis to transplant was shorter in Period 3 compared to earlier
periods (P< 0.01). There was no difference in time from diagnosis
to HSCT for patients transplanted in CR2 over 25 years
(P¼ 0.07). There was no increase in patients being transplanted
with persistent disease.
Overall median follow-up time for survivors was 75 months
(range 4–312 months). Median follow-up for Period 1 was
191 months (range 15–312 months), Period 2 was 133 months
TABLE II. Outcomes
Number of HSCTa
Period 1b Period 2c Period 3d
P-valuee41 48 47
5-Year OS (%) 35.70% 46.80% 78.90% <0.0001
Median survival (months) post-HSCT in months (range) 19 (1–312) 20 (0–198) 29 (2–108) 0.04
TRM 13 (31.7%) 15 (31.3%) 2 (4.3%) 0.0004
Relapses post-HSCT 16 (39%) 16 (33.3%) 12 (25.5%) 0.207
Median time (months) to relapse (range) 7 (3–47) 6 (1–42) 15 (4–30) 0.61
Second malignancy 1 (2.4%) 2 (4.2%) 1 (2.1%) 0.69
5-Year LFSf 49.60% 56.60% 68.20% 0.07
5-Year EFS 31.60% 40.40% 64.80% 0.0005
Acute GVHD
Grade 2–4 16 (39.0%) 11 (22.95%) 18 (38.3%) 0.35
Grade 3–4 10 (24.4%) 7 (14.6%) 9 (19.1%) 0.99
Grade 4 3 (7.3%) 3 (6.3%) 3 (6.4%) 0.94
Chronic GVHD 5 (12.2%) 5 (10.4%) 6 (12.8%) 0.79
Engraftment (days)
Median neutrophil engraftment (range) 17 (8–28) 20 (10–42) 18 (6–35) 0.68
Median platelet engraftment (range) 22 (11–75) 26 (12–95) 29 (15–91) 0.30
Hospital inpatient days (range) 30 (16–137) 30 (14–87) 34 (25–80) 0.92
aHaematopoietic stem cell transplant; bPeriod 1: 1/1/1984–31/8/1992; cPeriod 2: 1/9/1992–30/4/2001; dPeriod 3:1/5/2001–31/12/2009; eP value is
for Period 1 and 2 combined as compared to Period 3; fLeukemia-free survival.
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(58–198 months), Period 3 was 45 months (4–108 months). Those
who died had a median survival of 9 months (range 1–97months) in
Period 1, 4 months (range 0–45 months) in Period 2, and 21 months
(range 2–27 months) for Period 3.
HSCT Characteristics
There were 41 allogeneic HSCT for 40 patients in Period 1. One
patient received a second allogeneic HSCT, following relapse post-
HSCT. There were 48 HSCT episodes for 46 patients in Period 2.
This included two patients who received a second allogeneic HSCT,
one for graft failure and the other for relapse post-HSCT. In Period
3, there were 47 HSCT episodes and 44 patients. Subsequent
transplants in Period 3 were for relapse post-HSCT.Where a patient
received a subsequent HSCT, this was performed in the same period
as first HSCT. There were three graft failures, all in patients
receiving FRD HSCT (one in Period 1, two in Period 2).
Donor selection changed over time with significant decrease in
MSD (P¼ 0.02) and FRD grafts (P¼ 0.002), and significant
increase in UCT (P< 0.01) and MUD HSCT (P¼ 0.033). In Period
3, mostly UCT or MSD HSCT were performed (Table I). Four
double-cord UCTwere performed, all in Period 3 (Table III). There
were fewer CMV Dþ/Rþ pairs over time (P¼ 0.03) and a trend
towards more CMV D/R pairs in Period 3 (Table I).
There was no difference in median neutrophil and platelet
engraftment between periods for the entire group (Table II). Graft
subanalysis showed median neutrophil engraftment for UCT in
Period 3 was significantly faster than Period 2 (Table III). UCT
matching improved over time, with a greater percentage of 5/6
matched cords between Period 2 and 3 (Table III). In Period 3 UCT,
there was a trend towards higher median total nucleated cell doses,
although numbers are small (Table III).
There was no significant difference in speed to engraftment for
other grafts over time (Table IV). For the 25-year period, median
platelet engraftment was significantly longer for UCT (46 days,
range 19–91 days) compared to other grafts (P<0.001). Engraft-
ment times are listed in Table III (UCT) and Table IV (other grafts).
Clinical Outcomes
Survival for 25-year period. Overall, 5-year EFS was 45.8%,
5-year OS 53.9%, and 5-year LFS 58.8% (Supplementary Fig. 1).
TRM was 22.1%. Corresponding survival figures according to
HSCT period are listed in Table II. Survival outcomes over 25 years,
stratified for remission status, are depicted in Supplementary Fig. 1.
There was no significant difference in 5-year OS between patients
transplanted in CR1 and those transplanted in CR2 (66% vs. 51.2%,
P¼ 0.25). TRM for patients in CR1 was not significantly different
over 25 years compared to CR2 (9% vs. 26.2%, P¼ 0.14).
Survival. Significant improvements in survival were observed
when Periods 1 and 2 combined (1/1/1984–30/4/2001) were
compared to Period 3 (1/5/2001–31/12/2009).
EFS. 5-year EFS improved significantly over time, from
36.5% (Periods 1 and 2) to 64.8% (Period 3; P¼ 0.0005). When
stratified for remission status, 5-year EFS significantly improved for
patients in CR2 over time, increasing from 35.9% to 60.6%
(P¼ 0.0093). There was a trend towards improved EFS for patients
transplanted in CR2 (P¼ 0.0598).
OS. There was a significant increase in 5-year OS from 41.8%
(Periods 1 and 2) to 79% (Period 3; P< 0.0001). This improvement
remainedwhen stratified for remission status. 5-year OS for patients
transplanted in CR2 increased from 42.7% (Periods 1 and 2) to
75.4% (Period 3; P¼ 0.0052) and from 41.7% to 79%, respectively
for CR2 (P¼ 0.0006; Fig. 1).
Survival for graft type over 25-year period. Over 25 years,
5-year OS was 53.4% for MSD, 42.9% for FRD, 50.6% for MUD,
and 68.4% for UCT. TRMwas highest for FRD (39.2%) and ranged
between 15% and 25% for other graft types.
Graft survival per period. There was a significant improve-
ment in 5-year OS for patients receiving MSD and UCT over time
(Fig. 2). Five-year OS forMSD in Periods 1 and 2 was 44.1% versus
85.7% in Period 3 (P¼ 0.0093). Five-year OS for UCTwas 37.5%
for Period 2 and 79.3% in Period 3 (P¼ 0.0030). Significant TRM
reduction was seen only inMSD andUCT groups. TRM for patients
undergoing MSDHSCT for Periods 1 and 2 was 26.9%, and 0% for
Period 3 (P¼ 0.036). TRM for patients undergoingUCT in Period 2
was 40% and 6.25% for Period 3 (P¼ 0.0098). In Period 3,
there was no significant difference in OS (P¼ 0.80) and TRM
(P¼ 0.3329) between recipients of MSD and UCT. Comparative
5-year OS for MUD HSCTwas 41% for Periods 1 and 2 and 65.6%
for Period 3 (P¼ 0.17).
TRM. TRM significantly decreased from 33% (Periods 1 and
2) to 5% (Period 3; P¼ 0.0004). TRM for patients transplanted in
CR2 dropped from 31.2% (Periods 1 and 2) to 9.3% for Period 3
(P¼ 0.0417) and forCR2 from33.6% to 7.3% (P¼ 0.0083) (Fig. 1).
TABLE III. UCT Matching, TNC, and Engraftment
Total allogeneic transplants
Period 1a Period 2b Period 3c Total
P-value41 48 47 136
UCTd 0 8 21 29 <0.001
4/6 match 4 (50%) 2 (10%) 6 (20.7%) 0.028
5/6 match 2 (25%) 11 (52.4%) 13 (44.8%) 0.23
6/6 match 2 (25%) 4 (19%) 6 (20.7%) 0.75
Double cord transplante 0 4 (19%) (35/6 match, 14/6) 4 (13.8%)
Median TNCf (range) 3.35 (0.6–5.0) 4.7 (0.5–8.4) 4.7 (0.5–8.4) 0.08
Median neutrophil engraftment (days, range) 25.5 (18–34) 16 (6–33) 20 (6–34) 0.014
Median platelet engraftment (days, range) 60.5 (19–84) 40.5 (23–91) 46 (19–91) 0.64
Median hospital days (range) 41 (29–87) 45 (29–80) 42 (29–87) 0.16
aPeriod 1: 1/1/1984–31/8/1992; bPeriod 2: 1/9/1992–30/4/2001; cPeriod 3:1/5/2001–31/12/2009; dUmbilical cord blood transplant; eMatching for
double cord transplants was according to the least matched cord; fTotal nucleated cells 107/kg.
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TRM causes. Deaths from interstitial pneumonitis (IP),
infection and GVHD decreased over time. Causes of TRM in
Periods 1 and 2were predominantly IP andGVHD. In Period 1, there
were 15 cases of IP, including two CMV and 13 cases with no
organism identified (idiopathic). Of these, seven patients died,
including both patients with documented CMV. Period 2 also had 15
cases of IP, with five CMV, three PJP, and seven idiopathic. Of these,
10 patients died, including four CMVand three patients with PJP and
three idiopathic cases. One patient died from IP in Period 3 (PJP).
GVHD claimed four patients in Period 1 and two patients in
Period 2. In Period 1, three patients had multi-organ failure,
compared to none in later periods. There were only two TRM
deaths in Period 3. There were no deaths from VOD. Where TRM
was multi-factorial (five patients in Period 1, three patients in
Period 2 and one in Period 3), the main factors were GVHD and
infection.
Relapse. The 5-year cumulative incidence of relapse did not
vary over time (Periods 1 and 2 vs. Period 3: 46.5% vs. 31.6%,
P¼ 0.07) nor when stratified for remission status. Five-year
cumulative incidence of relapse for patients transplanted in CR2
was 50.1% in Periods 1 and 2 compared to 40.8% in Period 3
(P¼ 0.3229) and for CR2 was 47.2% and 34.1%, respectively
(P¼ 0.1687; Fig. 1). There was no difference in LFS stratified by
graft type (Supplementary Appendix I).
HSCT-related complications. Therewere more bacterial and
viral (non-CMV) infections post-HSCT in Period 3 (P¼ 0.001,
P¼ 0.035, respectively; Table IV). CMV and fungal infection
rates were unchanged at 15% and 17%, respectively in Period 3
(Table IV).
Despite increased use of unrelated donor HSCT, there was no
overall increase in GVHD (Table II). Following UCT, there was
significantly more Grade 2–4 aGVHD compared to MUD
(P¼ 0.018) and MSD HSCT (P¼ 0.046). Incidence of Grade
3–4 aGVHD for UCT was 24.1%, and Grade 2–4 was 51.7%.
Equivalent aGVHD figures for other grafts were: MUD Grade 3–
4: 12.5%, Grade 2–4: 20.89%; MSD 17.7%, 29%; FRD 23.8%,
33.3%, respectively. Chronic GVHD rates were similar over time
(Table II).
Length of stay. There was no difference in length of hospital
stay over periods (Tables II and III) or between graft types
(P¼ 0.54).
DISCUSSION
Our data show significant improvement over time in EFS and
OS post-HSCT for pediatric ALL, despite significant increase in
unrelated donor HSCT. Rates of relapse and major HSCT-related
complications, such as severe GVHD, remained steady. The
major contributor to improved survival was significant TRM
reduction.
We have shown greatest survival and TRM improvements for
patients undergoingMSD and UCT. UCT TRM and OS trends over
time have not been the focus of previous papers [16,22,35,36]. We
observed a significant survival advantage in Period 3 UCT. There
are several contributors to this, including better graft selection, with
significantly smaller degree of mismatch and trend towards a higher
median TNC. This resulted in significantly faster median neutrophil
engraftment for Period 3 UCT. Survival benefits of choosing better
matched UCT units, with TNC >3 107/kg are documented [35].
Total nucleated cell dose alone did not account for the survival
benefit in UCT in our cohort, as therewas no difference between cell
doses for survivors and those who died (median 4.7 107/kg vs.
3.9 107/kg, P¼NS).
TABLE IV. Infections (All Grafts) and Engraftment (Other Than Cords)
Total HSCTa
Period 1b Period 2c Period 3d Total
P-value41 48 47 136
Confirmed infectionse (total number, % of HSCT)
Bacterial 13 (31.7%) 15 (31.3%) 30 (63.8%) 58 (42.7%) 0.001
Viral (except for CMV) 11 (26.8%) 8 (16.7%) 19 (40.4%) 38 (27.9%) 0.035
CMV 5 (12.2%) 7 (14.5%) 7 (15%) 19 (14%) 0.927
Fungal 3 (7.3%) 6 (12.5%) 8 (17%) 17 (12.5%) 0.395
PJPf 0 3 (6.3%) 1 (2.1%) 4 (2.9%) 0.206
Outcomes by Graft type (days) Period 1 Period 2 Period 3 Total P-value
MSDg n¼27 n¼20 n¼15 n¼62
Median neutrophil engraftment (range) 17 (8–28) 20 (13–42) 19 (12–35) 19 (8–42) 0.14
Median platelet engraftment (range) 21 (12–75) 24 (15–90) 20.5 (17–34) 21 (12–90) 0.63
Median hospital days (range) 27 (14–147) 27 (16–147) 27 (14–87) 27 (14–147) 0.969
FRDh n¼12 n¼8 n¼1 n¼21
Median neutrophil engraftment (range) 16 (8–28) 15 (13–22) N/A 16 (8–28) 1
Median platelet engraftment (range) 26.5(21–56) 25 (24–33) N/A 25.5 (17–56) 1
Median hospital days (range) 62 (19–93) 30 (23–78) N/A 38 (19–93) 0.052
MUDi n¼2 n¼12 n¼10 n¼24
Median neutrophil engraftment (range) 13.5 (11–16) 20(10–25) 12.5(10–28) 15.5 (10–28) 0.231
Median platelet engraftment (range) 11.5 (11–12) 23 (12–95) 17 (15–34) 19 (11–95) 0.22
Median hospital days (range) 40 (33–46) 30 (21–67) 34 (25–48) 33 (21–67) 0.45
aHematopoeitic stem cell transplant; bPeriod 1: 1/1/1984–31/8/1992; cPeriod 2: 1/9/1992–30/4/2001; dPeriod 3:1/5/2001–31/12/2009; eSeveral
infections were often documented in the one patient; fPneumocystis jirovecii pneumonia; gMatched sibling donor; hFamily-related donor; iMatched
unrelated donor.
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Our HSCT outcomes for ALL compare favorably with national
and international studies [12,16,22,37–41]. Despite a significant
shift towards alternate donor HSCT, overall engraftment times
and length of initial hospital stay were unchanged. There
was a significant increase in bacterial and viral (non-CMV)
infections post-HSCT over time, but a decrease in IP. Discharge
criteria remained the same over time. This suggests we
are managing treatment-related toxicities with well-directed
supportive care strategies. The increased incidence of bacterial
and viral (non-CMV) infections probably reflects increased use
of immunosuppressive therapies in Period 3, and improved
testing modalities. CMV, PJP, and fungal infection incidence is
unchanged over time, possibly reflecting disease prophylaxis in
Period 3.
Our data show that contemporary HSCToutcomes are significant-
ly improved and that outcomes for patients undergoing MSD and
UCT are equivalent. This is consistent with previous literature [13].
Retrospective studies showed equivalent outcomes for MUD and
UCT [35,42]. One recent study suggested MSD might be superior to
alternate donor HSCT; however UCT data were not analyzed [21].
We postulate that improvedOS byway of reduced TRM is due to
multiple factors. These are likely to include selection of better
matched UCT units with higher TNC doses [43] resulting in faster
neutrophil engraftment times, a shorter time to transplant [27], better
Fig. 1. Significant recent improvement in survival and reduced TRM. Periods 1 and 2: 1/1/1984–30/4/2001 (n¼ 89), Period 3: 1/5/2001–31/12/
2009 (n¼ 47).A and B: Overall survival post HSCT for Periods 1 and 2 compared to Period 3, for all patients (A) and for patients inCR2 (B);C
andD: TRM post HSCT for Period 1 and 2 compared to Period 3, for all patients (C) and for patients inCR2 (D);E and F: Relapse post HSCT for
Period 1 and 2 compared to Period 3, for all patients (E) and for patients in CR2 (F).
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supportive care practices, availability of broader antimicrobials,
improved prevention of and monitoring for CMV infection [44] and
aggregate experience caring for HSCT patients [26]. Improvements
in HSCT care have resulted in survival benefits for contemporary
patients undergoing HSCT for high-risk ALL [45]. Units subjected
to external audit have improved post-HSCT outcomes [46]. We
expected to see improvement inMUDoutcomes, due to introduction
of high-resolution typing [3,14,28,47], but small numbers may have
limited analysis.
The significant increase in patients transplanted in CR1 in
Period 3 is not responsible for change in survival and TRM
outcomes, as these significant improvements were also observed for
patients transplanted in CR2. Pre-HSCT status of patients
transplanted in CR2 was probably similar over time, as their
median time to HSCT was unchanged over time.
Published studies, not confined toALL in children, show reduced
TRM over time [17,18,26,27]. Results are conflicting regarding
TRM trends over time in pediatric ALL HSCT. Two publications
reported significant improvement in OS and reduced TRM [16,22].
Another found no difference over time for OS post-unrelated HSCT,
but did not discuss TRM trends for year of transplant [25].
This study was a single-center, retrospective analysis, with
relatively small patient numbers. A strength of the study is uniform
transplant practice since 2004, which represents the majority of
Period 3. There was considerable heterogeneity in transplant
practices in Periods 1 and 2. Uniform reporting of pre-HSCT
performance scores would have provided additional comparison,
although a surrogate marker, such as time from diagnosis to HSCT,
has shown no change over time for patients transplanted in CR2.
The incidence of aGVHD (Grades 2–4) was equivalent to
retrospective series that included pediatric ALL [22,40,48]. Rates
of aGHVD (Grade 3–4; 19.9%) were consistent with one
prospective UCT study [43], but higher than another of MSD and
MUD HSCT [3]. The higher proportion of UCT in our study likely
contributed to this result. Higher aGVHD rates in UCT, as
compared to other donor sources in our series, did not increase TRM
or reduce relapse rates.
Post-HSCT relapse rates in our study, consistent with published
ranges (18–37%) [3] were stable. Median follow-up times,
including for Period 3 (median 45 months) were sufficient for
detection of most relapses [20,27]. Although there was significant
increase in TBI use in Period 3, this did not result in improved
leukemic control, as rates of relapse were unchanged. Some
pediatric ALL studies demonstrate reduction in post-HSCT
relapse [27], while others do not [16,20,22,25,49]. The impact of
increased numbers of patients in CR1 being transplanted on relapse
rates is unclear. Taken together, this indicates that strategies to
reduce post-HSCT relapse remain a priority.
Further studies using MRD may help determine extent of pre-
HSCT cytoreduction [16], and help assess if contemporary patients
in CR2 have more treatment-resistant disease [16,25] or increased
risk of post-HSCT relapse [20,49]. Pre-transplant MRD>103 and
disease status at transplant are the strongest predictors of relapse [4–
8,13]. Additional factors may lead to increased relapse [42,43,50],
including novel single nucleotide polymorphisms [51] and CMV
D/R status [48].
Discovery of new cytoreductive agents [52,53] and establishing
therapeutic pathways for post-HSCT MRD monitoring [4]
are important. Prospective randomized pediatric HSCT studies
need to compare UCT with both MSD and MUD outcomes, and
HSCT versus chemotherapy-alone regimens. Validated pre-HSCT
algorithms that incorporate performance scores and estimate TRM
are required to assist in physician decision-making [17,25,54].
We found that contemporary outcomes for HSCT for pediatric
ALL are significantly improved, due to several mechanisms, despite
increased use of unrelated donors. TRM decreased significantly
over 25 years. Relapse rates are static. International collaboration is
required to target and develop novel treatment strategies for patients
at high risk of relapse post-HSCT.
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